Drug wholesaler AmerisourceBergen laid out $2.5 billion to buy the PharMEDium sterile drug compounding pharmacy operation, believing it will be a growth driver. But so far, the operations have become a regulatory quagmire for the company, now resulting in a DOJ investigation and a gut-kick to its earnings.Original Article
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.